Sergio Traversa, Chief Executive Officer and Director of Relmada Therapeutics, Inc. (NASDAQ:RLMD), filed a Form 4 on September 11, 2026, disclosing two open market purchases of common stock totaling 200,000 shares on September 9 and September 10, 2026.

Key Highlights

  • First purchase: Sergio Traversa acquired 100,000 shares of common stock on September 9, 2026, at a weighted average price of $4.18 per share, with individual transaction prices ranging from $4.15 to $4.22 per share.
  • Second purchase: An additional 100,000 shares were acquired on September 10, 2026, at a weighted average price of $4.10 per share, with individual transaction prices ranging from $4.03 to $4.11 per share.
  • Total beneficial ownership: Following both transactions, Traversa beneficially owns 1,500,000 shares of common stock directly.
  • Transaction type: Both transactions were coded "P" (open market purchase), according to the filing.
  • Reporting person roles: Traversa is identified in the filing as both a Director and Chief Executive Officer of Relmada Therapeutics, Inc.

Relmada CEO Traversa's Two-Day Open Market Share Purchases

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Sergio Traversa, Chief Executive Officer and Director of Relmada Therapeutics, Inc. (NASDAQ:RLMD), purchased a combined 200,000 shares of the company's common stock across two consecutive trading days. Both transactions were conducted in the open market and are reported as direct ownership.

The filing discloses that on September 9, 2026, Traversa acquired 100,000 shares at a weighted average price of $4.18 per share. The filing notes that individual purchase prices for that day ranged from $4.15 to $4.22 per share, inclusive. Following that transaction, Traversa's directly held beneficial ownership stood at 1,400,000 shares. The next day, September 10, 2026, Traversa acquired another 100,000 shares at a weighted average price of $4.10 per share, with individual transaction prices ranging from $4.03 to $4.11 per share, inclusive. After this second purchase, his directly held beneficial ownership totaled 1,500,000 shares.

The filing explains that each reported share count represents "an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices," and that Traversa "undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range." No derivative securities transactions were reported. The Form 4 was signed by Sergio Traversa on September 11, 2026.

What Was Disclosed

The filing reports two open market purchases of Relmada Therapeutics common stock by CEO Sergio Traversa on September 9 and September 10, 2026, totaling 200,000 shares, bringing his direct beneficial ownership to 1,500,000 shares.